PD L1 News and Research

RSS
Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

New investigational immunotherapy benefits people with advanced urothelial bladder cancer

New investigational immunotherapy benefits people with advanced urothelial bladder cancer

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

New era of lung cancer therapy close to dawning

New era of lung cancer therapy close to dawning

PD-L1 plays important role in pathogenesis of multiple sclerosis

PD-L1 plays important role in pathogenesis of multiple sclerosis

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Experimental drug nivolumab shrinks tumors in patients with advanced melanoma

Biologists discover effective strategy that could prevent immune system from rejecting grafts

Biologists discover effective strategy that could prevent immune system from rejecting grafts

Researchers develop possible new method for treating pancreatic cancer

Researchers develop possible new method for treating pancreatic cancer

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics acquires Concortis Biosystems

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.